옵션 체인은 다양한 행사가격과 만기일에 대한 Birkenstock Holding의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Birkenstock Holding에 대한 시장 심리를 평가합니다..

Birkenstock Holding (NYSE:BIRK) 주식, 옵션 체인

Birkenstock Holding

Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. It sells its products through two main channels: business-to-business (B2B) which comprises sales made to established third-party store networks, and direct-to-consumer (DTC) which comprises sales made on globally owned online stores through the Birkenstock.com domain and sales made in Birkenstock retail stores. The company's reportable segments are based on its regional hubs and include: the Americas which is also its key revenue-generating segment; Europe; and Australia, Japan, India, China, and the United Arab Emirates (APMA).

Kuala,Lumpur,,Malaysia,-,December,01,,2023:,Interior,Shot,Of

Analyst Color

News

Price Target

Reiteration

Analyst Ratings

General

BBWI

BIRK

BOOT

BURL

LEVI

LULU

OLLI

ROST

URBN

JP모건 애널리스트 매튜 보스(Matthew R. Boss)에 따르면, 1분기 소매업 펀더멘털은 예상에 근접한 추세를 보이고 있으며, 부활절이 있는 4월 말에 더 강력한 모멘텀이 나타날 조짐을 보이고 있다. 

JP모건 애널리스트 &#34;관세 압력 증가 시 소비자들은 할인 소매업체 찾을 것&#34;

DRI, Darden

Large Cap

Movers

Trading Ideas

CHWY

DOCS

KVYO

NBIX

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

Moderna

APTV

BGNE

MRNA

POOL

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 월그린스 부츠 얼라이언스(NASDAQ:WBA)의 주가는 회사가 혼합된 3분기 실적을 보고하고 2024년 지침을 컨센서스 추정치보다 낮게 낮춘 후 24.12% 하락했다. 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

모더나와 월그린스는 지난주 최악의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)

Birkenstock Holding PLC

Birks Group Inc

WIIM

ICHR

Ichor Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 guidance below estimates.

LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>), a leading U.S.-based manufacturer of commercial and industrial lighting and display solutions, announced the renewal of its partnership as an Official Lighting Sponsor of USA Pickleball. This extended collaboration highlights LSI's commitment to advancing America's fastest-growing sport through innovative lighting technologies that enhance visibility, safety, and the overall playing experience.

LYTS

LSI Industries Renews Partnership As Official Lighting Sponsor Of USA Pickleball

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 5.59%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and cut the price target from $14 to $10 on March 5, 2025. This analyst has an accuracy rate of 73%.</li>
<li>B of A Securities analyst Jason Gerberry maintained an Underperform rating and slashed the price target from $11 to $10 on Feb. 28, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On April 14, Viatris named Hemanth J. Varghese as Chief Strategy Officer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">VTRS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="918" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png" alt="" class="wp-image-902820" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-768x701.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.95%</li>
<li>Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $65 on April 22, 2025. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and slashed the price target from $60 to $54 on April 11, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="907" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png" alt="" class="wp-image-902821" style="width:561px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-768x714.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 4.10%</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and cut the price target from $20 to $19 on Feb. 5, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: The company is expected to announce quarterly earnings today.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest PINC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="906" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png" alt="" class="wp-image-902822" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-768x714.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

PINC

VTRS

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $180 to $190.

JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $190

Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 42.11 percent decrease over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $148.77 million which beat the analyst consensus estimate of $139.89 million by 6.34 percent. This is a 7.38 percent increase over sales of $138.55 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Marcus Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $148.77M Beat $139.89M Estimate

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) lowers FY2025 sales outlook from $2.50 billion-$2.55 billion to $2.38 billion-$2.48 billion vs $2.54 billion estimate.

Guidance

GBTG

Global Business Travel Lowers FY2025 Sales Guidance from $2.50B-$2.55B to $2.38B-$2.48B vs $2.54B Est

OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.46) by 18.49 percent.

OKUR

OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) sees Q2 sales of $615.000 million-$635.000 million vs $652.62 million analyst estimate.

Global Business Travel Sees Q2 Sales $615.000M-$635.000M vs $652.62M Est

SEDG

SolarEdge Technologies shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

Capitolis Taps Pagaya, Goldman Sachs Veteran Amol Naik As Coo To Lead Growth Push

Peabody Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.22 by 22.73 percent. This is a 6.9 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $937.00 million which missed the analyst consensus estimate of $949.80 million by 1.35 percent. This is a 4.74 percent decrease over sales of $983.60 million the same period last year.

Peabody Energy Q1 EPS $0.27 Beats $0.22 Estimate, Sales $937.00M Miss $949.80M Estimate

JELD

JELD-Wen Holding shares are trading lower. The comapny issued Q1 financial results.

TCMD

Tactile Systems Technology shares are trading lower after the company reported worse-than-expected Q1 sales results and lowered its FY25 sales guidance below estimates.

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.08 by 100 percent. This is a 500 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $621.00 million which missed the analyst consensus estimate of $633.58 million by 1.99 percent. This is a 1.80 percent increase over sales of $610.00 million the same period last year.

Global Business Travel Q1 EPS $0.16 Beats $0.08 Estimate, Sales $621.00M Miss $633.58M Estimate

JP Morgan analyst Arun Jayaram maintains Cactus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) with a Neutral and lowers the price target from $54 to $52.

JP Morgan Maintains Neutral on Cactus, Lowers Price Target to $52

Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.01) by 13.86 percent. This is a 10.13 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $72.00 thousand which beat the analyst consensus estimate of $70.13 thousand by 2.67 percent. This is the same as the same period last year.

VRDN

Viridian Therapeutics Q1 EPS $(0.87) Beats $(1.01) Estimate, Sales $72.00K Beat $70.13K Estimate

Fabrinet Ordinary shares are trading lower. The company reported Q3 financial results

JP Morgan analyst Sebastiano Petti maintains Cable One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>) with a Neutral and lowers the price target from $325 to $222.

CABO

JP Morgan Maintains Neutral on Cable One, Lowers Price Target to $222

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading lower after the company reported Q1 financial results. Also, the company issued Q2 revenue guidance below estimates.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $30 price target.

BCRX

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

Press Releases

Birkenstock Announces Third Quarter 2024 (Ended June 30, 2024) Results Date and Conference Call

Birkenstock Reports Record Third Quarter Revenue, up 19% Year-Over-Year, Driven by Continued Strong and Growing Consumer Demand

Events

Birkenstock Announces September Conference Participation

Birkenstock Announces Fourth Quarter and Full Fiscal Year 2024 (Ended September 30, 2024) Results Date and Conference Call

Birkenstock Reports Fiscal 2024 Results: Revenue Growth and Adjusted EBITDA Ahead of Expectations

Birkenstock Announces First Quarter 2025 (Ended December 31, 2024) Results Date and Conference Call and January Conference Participation

Management

Ivica Krolo Appointed as New Chief Financial Officer of the Birkenstock Group

Birkenstock Reports Fiscal First Quarter 2025 Results: Revenues Up 19%

Birkenstock Announces Fiscal Second Quarter 2025 (Ended March 31, 2025) Results Date and Conference Call

Comments

Birkenstock Holding

Birkenstock Holding (BIRK) 옵션

Birkenstock Holding (NYSE:BIRK) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌